Phenanthroline

Phenanthroline

SCHEMBL29401908

[Ru].c1cnc2c(c1)ccc1cccnc12

nearest known ligand 0.94

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCR1 P32246 5/20 0.94
▸ CCR8 P51685 5/20 0.94
▸ LMNA P02545 4/20 0.94
▸ CCR5 P51681 3/20 0.94
▸ KDM4E B2RXH2 3/20 0.94
▸ MMP2 P08253 2/20 0.94
▸ TSHR P16473 2/20 0.94
▸ MAPT P10636 2/20 0.94
▸ HTT P42858 2/20 0.94
▸ SMN1; SMN2 Q16637 2/20 0.94
▸ TDP1 Q9NUW8 2/20 0.94
▸ GMNN O75496 1/20 0.94
▸ TP53 P04637 1/20 0.94
▸ HSP90AA1 P07900 1/20 0.94
▸ CYP3A4 P08684 1/20 0.94
▸ CYP2D6 P10635 1/20 0.94
▸ MMP9 P14780 1/20 0.94
▸ ALOX15 P16050 1/20 0.94
▸ NFKB1 P19838 1/20 0.94
▸ MMP8 P22894 1/20 0.94

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenanthroline SCHEMBL29367240 1.00 CCR1 (0.94) CCR1CCR8LMNACCR5KDM4E
Phenanthroline SCHEMBL7268958 1.00 CCR1 (0.94) CCR1CCR8LMNACCR5KDM4E
Phenanthroline SCHEMBL345410 1.00 CCR1 (0.94) CCR1CCR8LMNACCR5KDM4E
Phenanthroline SCHEMBL5347299 1.00 CCR1 (0.94) CCR1CCR8LMNACCR5KDM4E
Phenanthroline SCHEMBL1681332 1.00 CCR1 (0.94) CCR1CCR8LMNACCR5KDM4E
Phenanthroline SCHEMBL1237620 0.97 CCR1 (0.89) CCR1CCR8LMNACCR5KDM4E
Phenanthroline SCHEMBL28911275 0.97 CCR1 (0.89) CCR1CCR8LMNACCR5KDM4E
Phenanthroline SCHEMBL15397666 0.97 CCR1 (0.89) CCR1CCR8LMNACCR5KDM4E
Phenanthroline SCHEMBL8845760 0.97 CCR1 (1.00) CCR1CCR8LMNACCR5KDM4E
Phenanthroline SCHEMBL8312 0.97 CCR1 (1.00) CCR1CCR8LMNACCR5KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4203941-A1 COMBINATION THERAPY FOR REDUCING DRUG-INDUCED NEPHROTOXICITY, DYSLIPIDEMIA AND HYPERGLYCEMIA Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) 2023-07-05 — — EP disclosed
EP-4117682-A1 MODIFIED NUCLEOTIDES AND USES THEREOF Singular Genomics Systems, Inc. (US) 2023-01-18 — — EP disclosed
WO-2022044014-A1 COMBINATION THERAPY FOR REDUCING DRUG-INDUCED NEPHROTOXICITY, DYSLIPIDEMIA AND HYPERGLYCEMIA YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2022-03-03 — — WO disclosed
Send feedback